advisory panels

The future of Vascepa sales, and Amarin, could hinge on next week's panel
The future of Vascepa sales, and Amarin, could hinge on next week's panel
EP Vantage
Amarin
Vascepa
FDA
advisory panels
M&A
Flag link:
FDA Ad Com thumbs down on full Makena approval
FDA Ad Com thumbs down on full Makena approval
Seeking Alpha
Makena
preterm birth
Amag Pharmaceuticals
FDA
advisory panels
Flag link:
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Endpoints
Shionogi
FDA
advisory panels
antibiotics
cefiderocol
UTIs
Flag link:
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
Endpoints
Shionogi
FDA
advisory panels
antibiotics
UTIs
cefiderocol
Flag link:
GSK's oral nicotine spray wins divided FDA panel's backing despite abuse risks
GSK's oral nicotine spray wins divided FDA panel's backing despite abuse risks
Fierce Pharma
GSK
FDA
advisory panels
OTC
Flag link:
An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening
An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening
Stat
FDA
advisory panels
peanut allergy
Aimmune Therapeutics
Palforzia
Flag link:
Amarin's Vascepa buzzkill: FDA stalls label review with surprise panel meeting
Amarin's Vascepa buzzkill: FDA stalls label review with surprise panel meeting
Fierce Pharma
Amarin
Vascepa
advisory panels
FDA
Flag link:
13 Keys to a Successful FDA Advisory Committee Meeting
13 Keys to a Successful FDA Advisory Committee Meeting
RAPS.org
FDA
advisory panels
Flag link:
Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom
Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom
Endpoints
FDA
Amarin
Vascepa
advisory panels
earnings
Flag link:
FDA cancels panel review of Intra-Cellular’s schizophrenia drug, causing shares to tumble
FDA cancels panel review of Intra-Cellular’s schizophrenia drug, causing shares to tumble
Stat
Intra-Cellular Therapies
FDA
advisory panels
schizophrenia
lumateperone
Flag link:
FDA overrides adcomm opinions a fifth of the time, study finds — but why?
FDA overrides adcomm opinions a fifth of the time, study finds — but why?
Endpoints
FDA
advisory panels
Flag link:
U.S. advisory panel stops short of broad recommendations for two common vaccines
U.S. advisory panel stops short of broad recommendations for two common vaccines
Stat
FDA
vaccines
HPV
pneumonia
advisory panels
Merck
Gardasil
Pfizer
Prevnar 13
Flag link:
Paclitaxel-Coated Devices’ Late Mortality Signal Not Well Understood, FDA Panel Hears
Paclitaxel-Coated Devices’ Late Mortality Signal Not Well Understood, FDA Panel Hears
RAPS.org
FDA
paclitaxel
devices
advisory panels
Flag link:
FDA panel does not back broad reach of Sanofi's dengue vaccine
FDA panel does not back broad reach of Sanofi's dengue vaccine
BioCentury
Sanofi
dengue
Dengvaxia
FDA
advisory panels
Flag link:
FDA experts offer a big thumbs up for J&J’s flawed application to market esketamine for major depression — but trial failures, safety questions spur concerns
FDA experts offer a big thumbs up for J&J’s flawed application to market esketamine for major depression — but trial failures, safety questions spur concerns
Endpoints
JNJ
FDA
advisory panels
esketamine
major depression
Flag link:
Approving J&J's new depression drug would be an unusual move for the FDA
Approving J&J's new depression drug would be an unusual move for the FDA
BioPharma Dive
JNJ
esketamine
FDA
advisory panels
Flag link:
FDA advisers divided on Sanofi’s oral type 1 diabetes drug
FDA advisers divided on Sanofi’s oral type 1 diabetes drug
Pharmaforum
Sanofi
Lexicon Pharmaceuticals
type 1 diabetes
Zynquista
FDA
advisory panels
sotagliflozin
Flag link:
Amgen's once-dismissed osteoporosis drug Evenity 'back in the game' after rosy FDA panel vote
Amgen's once-dismissed osteoporosis drug Evenity 'back in the game' after rosy FDA panel vote
Fierce Pharma
Amgen
osteoporosis
Evenity
romosozumab
FDA
advisory panels
Flag link:
Naloxone Availability: FDA Meeting Next Week
Naloxone Availability: FDA Meeting Next Week
RAPS.org
FDA
advisory panels
opioids
opioid crisis
opioid overdose
Naloxone
Flag link:
FDA advisory panel to mull transvaginal mesh
FDA advisory panel to mull transvaginal mesh
Mass Device
FDA
devices
transvaginal mesh
advisory panels
Flag link:

Pages